Introduction:
French biotechnology company Sensorion SA has achieved significant milestones in its Phase II trial for the preservation of residual hearing loss. The company reported new efficacy endpoint data for its drug SENS-401, which aims to protect and preserve inner ear tissue to prevent progressive hearing impairment.
- SENSORION conducted a Phase II trial for the preservation of residual hearing loss in adult patients following cochlear implantation.
- SENS-401, an orally available small molecule, reduced sudden hearing loss in patients compared to the control group.
- Patients treated with SENS-401 had a lower mean hearing loss at several frequencies compared to the control group.
- The presence of SENS-401 in the perilymph at a therapeutic level was confirmed in all patients sampled.
- SENSORION plans to present full final data in Q3 2024.
Conclusion:
SENSORION’s Phase II trial for the preservation of residual hearing loss has shown promising results. The use of SENS-401 in reducing sudden hearing loss and preserving residual hearing in patients after cochlear implantation highlights the potential therapeutic efficacy of the drug. These findings contribute to the development of novel treatments for hearing impairment and provide hope for patients with progressive or sequelae hearing impairment.
